Laboratorios Farmaceuticos Rovi, S.A. (LON: 0ILL)
London
· Delayed Price · Currency is GBP · Price in EUR62.90
+1.15 (1.86%)
Nov 22, 2024, 3:27 PM BST
Laboratorios Farmaceuticos Rovi Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 165 | 170.34 | 199.67 | 153.08 | 61.06 | 39.27 | Upgrade
|
| Depreciation & Amortization | 26.21 | 23.44 | 21.84 | 20.3 | 18.31 | 17 | Upgrade
|
| Other Amortization | 0.9 | 0.9 | 1.03 | 1.06 | 1.29 | 1.21 | Upgrade
|
| Loss (Gain) From Sale of Investments | 0.27 | 0.22 | -1.83 | -1.16 | 0.25 | -0.31 | Upgrade
|
| Loss (Gain) on Equity Investments | 0.1 | 0.13 | -0.2 | -0.18 | 0.03 | 0.2 | Upgrade
|
| Stock-Based Compensation | - | - | - | 1.4 | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | -0.04 | -0.04 | 0.04 | -0.27 | -0.24 | -0.28 | Upgrade
|
| Other Operating Activities | -35.14 | -47.28 | 74.03 | 39.24 | 29.94 | -2.48 | Upgrade
|
| Change in Accounts Receivable | -44.33 | 19.47 | -26.82 | -74.19 | 7.47 | -20.41 | Upgrade
|
| Change in Inventory | 19.67 | -29.29 | -71.59 | -23.43 | -70.4 | -67.23 | Upgrade
|
| Change in Accounts Payable | -8.22 | -23.92 | 41.67 | 35.36 | -0.81 | 23.95 | Upgrade
|
| Change in Other Net Operating Assets | 1.77 | -0.7 | -0.23 | -1.78 | -0.01 | 0.02 | Upgrade
|
| Operating Cash Flow | 126.18 | 113.25 | 237.6 | 149.44 | 46.88 | -9.04 | Upgrade
|
| Operating Cash Flow Growth | 5.33% | -52.34% | 58.99% | 218.80% | - | - | Upgrade
|
| Capital Expenditures | -60.32 | -53.79 | -50.72 | -40.22 | -39.34 | -25.9 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.15 | 0.38 | 0.08 | 0.03 | 0.06 | 0 | Upgrade
|
| Sale (Purchase) of Intangibles | -1.9 | -1.39 | -0.67 | -0.72 | -0.36 | -14.63 | Upgrade
|
| Investment in Securities | 1.63 | 1.29 | -5.85 | - | - | - | Upgrade
|
| Other Investing Activities | 0.28 | 1.49 | 0.01 | 0.07 | 0 | 0.05 | Upgrade
|
| Investing Cash Flow | -60.17 | -52.03 | -57.15 | -40.84 | -39.63 | -40.47 | Upgrade
|
| Long-Term Debt Issued | - | 0.73 | 1.4 | 1.34 | 1.43 | 47.03 | Upgrade
|
| Long-Term Debt Repaid | - | -13.65 | -6.77 | -6.19 | -13.18 | -21.24 | Upgrade
|
| Net Debt Issued (Repaid) | 57.15 | -12.92 | -5.37 | -4.85 | -11.75 | 25.79 | Upgrade
|
| Issuance of Common Stock | 22.92 | 52.64 | 77.77 | 42.33 | 37.49 | 4.87 | Upgrade
|
| Repurchase of Common Stock | -133.64 | -133.9 | -177.01 | -78.79 | -37.26 | -4.72 | Upgrade
|
| Common Dividends Paid | -56.45 | -69.05 | -51.01 | -21.13 | -9.7 | -4.42 | Upgrade
|
| Other Financing Activities | 5.18 | 2.39 | 1.08 | -0.29 | -0.3 | -0.09 | Upgrade
|
| Financing Cash Flow | -104.84 | -160.84 | -154.54 | -62.73 | -21.52 | 21.43 | Upgrade
|
| Net Cash Flow | -38.82 | -99.62 | 25.91 | 45.87 | -14.26 | -28.09 | Upgrade
|
| Free Cash Flow | 65.86 | 59.45 | 186.88 | 109.22 | 7.54 | -34.94 | Upgrade
|
| Free Cash Flow Growth | 8.08% | -68.19% | 71.10% | 1348.77% | - | - | Upgrade
|
| Free Cash Flow Margin | 8.24% | 7.17% | 22.85% | 16.84% | 1.80% | -9.16% | Upgrade
|
| Free Cash Flow Per Share | 1.23 | 1.12 | 3.50 | 1.97 | 0.14 | -0.63 | Upgrade
|
| Cash Interest Paid | 1.23 | 0.39 | 0.29 | 0.29 | 0.45 | 0.19 | Upgrade
|
| Cash Income Tax Paid | 38.44 | 40.86 | 43.89 | 23.86 | 6.04 | 8.13 | Upgrade
|
| Levered Free Cash Flow | 48.54 | 25.36 | 135.92 | 66.2 | -12.05 | -64.27 | Upgrade
|
| Unlevered Free Cash Flow | 50.44 | 25.95 | 136.45 | 66.76 | -11.38 | -63.86 | Upgrade
|
| Change in Net Working Capital | 47.29 | 80.36 | -6.38 | 28.78 | 38.11 | 67.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.